Genetic studies continue to strengthen the case for targeting microglia in Alzheimer’s disease. The harder task is ...

Building better biological AI models requires more than simply generating more data. Four initiatives launched or expanded in ...

FDA approved the first plasmid DNA-based immunotherapy in October, granting accelerated approval to Inovio’s Voceryq ...

Caspian is developing an oral menin inhibitor to regenerate patients’ own pancreatic beta cells, with plans to begin testing ...

The political action committees of the 10 largest drugmakers by 2025 global pharmaceutical sales, along with PhRMA and BIO, directed nearly all their ...

A single trading day offers limited evidence, but Friday’s sharp divergence between tech and large-cap biopharma stocks suggests the latter could ...

Washington spends enormous energy scrutinizing the policy positions of FDA commissioner nominees. But does it pay enough attention to whether they can ...

BioCentury’s analysis of first-in-human trials at ESMO 2026 highlights target innovation among translational ADC programs ...

FDA has at least eleven PDUFA dates on its November calendar, 10 of which are for new products. First up is PD-1 x VEGF ...

For more than a decade, it has been clear that U.S. clinical trials are too slow, too costly, and too far removed from the ...

Gilde’s Impact Council as a multi-stakeholder diligence engine — Former regulators, HTA leaders, payers, clinicians, and ...

Antibody-drug conjugates accounted for more first-in-human studies than any other modality at ESMO 2026, highlighting their ...